CXCL8 and breast carcinoma: When we treated LCC2 cells with bicalutamide, the expression of IL-8 was reduced, as revealed by qPCR (Figure 3e) and ELISA (Figure 3f), thus confirming that IL-8 expression in breast cancer can be governed by ARE and ERE activity.